Daraxonrasib (RMC-6236) delivered breakthrough results in the phase 3 RASolute 302 trial offering a major advance for patients with previously treated metastatic pancreatic ductal adenocarcinoma. The study enrolled 500 patients whose cancer had progressed after one prior chemotherapy regimen and compared oral daraxonrasib with standard chemotherapy options.
Patients treated with daraxonrasib achieved a median overall survival of 13.2 months, nearly double the 6.6–6.7 months seen with chemotherapy, reducing the risk of death by 60%. Median progression-free survival improved to about 7.3 months compared with 3.5 months, while the objective response rate reached 33.2% versus 11.8%.
The drug also showed better tolerability, with fewer severe side effects and a treatment discontinuation rate of just 1.2%, compared with 11.2% for chemotherapy. Patients experienced longer delays in pain worsening and quality-of-life decline. Experts say the results could establish daraxonrasib as a new standard of care for previously treated metastatic pancreatic cancer.